normalized mutation frequency of nucleotides occurring in the context of an RGYW/WRCY motif was compared to the expected mutation frequency by the goodness-of fit w 2 test. Mutation analysis of PAX-5, Rho/TTF, PIM-1 and c-MYC is summarized in Table 1 . Overall, the prevalence of aberrant SHM did not significantly differ between PMLBCL and DLBCL. Mutations targeting at least one of the four proto-oncogenes were found in 14/19 (73.6%) PMLBCL and 13/19 (68.4%) DLBCL, while mutations targeting more than one gene were found in 7/19 (36.8%) PMLBCL and 9/19 (47.3%) DLBCL. Each of the four genes analysed was altered in a significant fraction of PMLBCL and DLBCL, since PAX-5 was mutated in 9/19 (47.3%) PMLBCL and 7/19 (36.8%) DLBCL, RhoH/TTF in 6/19 (31.5%) PMLBCL and 8/19 (42.1%) DLBCL, PIM-1 in 3/19 (15.7%) PMLBCL and 7/19 (36.8%) DLBCL, and c-MYC in 6/19 (31.5%) PMLBCL and 5/19 (26.3%) DLBCL.
The detailed characterization of PAX-5, RhoH/TTF, PIM-1 and c-MYC mutations is reported in Tables 1 and 2 . Overall, the molecular profile of mutations was similar between PMLBCL and DLBCL. A total of 74 mutational events were detected in PMLBCL. The overwhelming majority of the mutations included single base-pair substitutions (n ¼ 66), whereas deletions of a short DNA stretch were observed in eight instances. Of the 66 single base-pair substitutions observed, 41 were transitions and 25 were transversions, with a transition/transversion ratio of 1.64 (expected 0.5; P ¼ 0.001). When considering all the nucleotide substitutions observed, analysis of the nucleotide exchange pattern showed that G þ C base pairs were targeted 3.33-fold more frequently than A þ T (expected 1.28; P ¼ 0.009). In all, 19 of 66 single base-pair substitutions detected in PMLBCL felt within RGYW/WRCY motifs. Considering all the genes together, the frequency of mutations targeting RGYW/ WRCY motifs was significantly higher than the frequency of mutations occurring outside RGYW/WRCY motifs (2.3 vs 1.3%; P ¼ 0.03). As mutations introduced by physiological SHM preferentially affect specific dinucleotides, 5 we also analysed the distribution of mutations within dinucleotide motifs. Considering together all the four proto-oncogenes, the mutation frequency was higher than expected in the following motifs: AA (4.3 vs 1.3%; Po0.0001), AG (3.0 vs 1.3%; P ¼ 0.028), GC (5.1 vs 1.1%; Po0.0001), GG (4.2 vs 1.1%; Po0.0001) and TA (4.6 vs 1.3%; P ¼ 0.003).
Among DLBCL, a total of 87 mutational events were detected. Mutations were preferentially represented by single base-pair substitutions (n ¼ 81), whereas only four deletions and two insertions of a short DNA stretch were observed. Of the 81 single base-pair substitutions, 42 were transitions and 39 were transversions, with a transition/transversion ratio of 1.07 (expected 0.5; P ¼ 0.02). Analysis of the nucleotide exchange pattern showed that G þ C base pairs were targeted 1.89-fold more frequently compared to A þ T (expected 1.28; P ¼ ns). In all, 41 out of 81 single base-pair substitutions felt within RGYW/WRCY motifs. The frequency of mutations targeting RGYW/WRCY motifs was significantly higher than the frequency of mutations occurring outside RGYW/WRCY motifs (5.0 vs 1.7%; Po0.0001). Similarly to PMLBCL, also in DLBCL the mutation frequency was higher than expected in specific dinucleotide motifs: AA (6.4 vs 1.5%; Po0.0001), AC (5.4 vs 1.4%; Po0.0001), AG (4.5 vs 1.6%; Po0.0001), AT (4.2 vs 1.7%; P ¼ 0.033), CT (4.4 vs 1.6%; Po0.0001), GC (5.1 vs 1.1%; Po0.0001), GG (3.5 vs 1.6%; Po0.0001) and TA (8.6 vs 1.5%; Po0.0001).
In PIM-1 and c-MYC, a number of mutations were located in coding exons and led to amino-acid substitutions, with potential functional consequences. In particular, among PMLBCL, one missense mutation in case 5 affected PIM-1 exon 2 leading to the substitution of Ala for Gly at position 28 of the amino-acidic sequence. Three missense mutations in cases 15 and 18 affected c-MYC exon 2, leading to the substitution of Ser for Pro at position 59, Glu for Gly at position 91 and Lys for Ser at position Table 1 Mutation analysis of PAX-5, RhoH/TTF, PIM-1 and c-MYC in PMLBCL and DLBCL Case Mutation type and position
T788C, C848G, C853A, A885T G971A, D1046-1048, G1079C G1161A, G1193C, C1207T, C1210A G1286T, G1308A, C1334G, G1347A D1434-1450 D4976-4980 frameshift  24  G1435T  A1428C  G1287C  D806-821  +GGG 1269   A459C, T477C, G479A  A619T, A693G, G694C  A777G, A853C, C855T  G881A, T901G, T916G  G924A, T947C, A957C  T976G, T987A, T992A  T1043G, G1061T C1756T
G904A, C905G, T906C, C1046T C1423T, +G 1417 G597A G875A
C1201T: His11Tyr C1087T Correspondence 64 (Table 1) . Among DLBCL, three missense mutations affected respectively PIM-1 exon 1 (case 27), leading to the substitution of Tyr for His at position 11; PIM-1 exon 2 (case 38), leading to the substitution of Asp for Gly at position 28; and PIM-1 exon 4 (case 30), leading to the substitution of Ser for Gly at position 99. One non-sense mutation affected PIM-1 exon 4 (case 38), truncating the amino-acidic sequence at position 127. With respect to c-MYC, a short DNA stretch deletion led to a frameshift mutation within exon 2 in case 23 (Table 1) . To investigate whether the aberrant mutational activity is ongoing in PMLBCL, we selected the gene that displayed the highest mutation frequency, namely PAX-5. Among PMLBCL carrying mutations of PAX-5, a subset of cases (n ¼ 4), shown by direct sequencing to carry the highest mutation frequency, were analysed for the presence of intraclonal heterogeneity. The results showed that, in all PMLBCL analysed, one or two predominant alleles recapitulate the mutations observed by direct sequencing of the PCR product, confirming their presence in the tumor clone (not shown). Ongoing SHM was found in the PAX-5 sequence of only 1/4 PMLBCL examined, namely case 5.
The implications of our results are two-fold. First, aberrant SHM is a frequent event in PMLBCL and may contribute to the pathogenesis of the disease. Second, because aberrant SHM targets both PMLBCL and DLBCL with similar prevalence, distribution and mutational pattern, our results disclose some degree of identity in the molecular pathogenesis of these two lymphoma types.
The molecular pathogenesis of PMLBCL is largely unknown. Here, we document that 73% PMLBCL are targeted by aberrant SHM of at least one of four proto-oncogenes, namely PAX-5, RhoH/TTF, PIM-1 or c-MYC. These genes encode proteins with different functions since they include both signal transducers (PIM-1 and Rho/TTF) and transcription factors (PAX-5 and c-MYC) involved in B-cell development/differentiation, proliferation and apoptosis. 3 Activation of PAX-5, RhoH/TTF, PIM-1 and c-MYC may be relevant for B-cell lymphomagenesis, since, as previously noted, these four genes represent known protooncogenes that have been implicated in lymphoma-associated chromosomal translocations. 3 In PMLBCL, aberrant SHM may alter the function of PAX-5, RhoH/TTF, PIM-1, and c-MYC by at least two modalities. As mutations cluster around the gene 5 0 untranslated region, it is conceivable that mutations may deregulate gene transcription by affecting specific regulatory regions, with a mechanism analogous to that observed for BCL-6 and c-MYC in DLBCL and Burkitt's lymphoma, respectively. 6, 7 A subset of mutations of c-MYC and PIM-1 in PMLBCL lead to amino-acid substitutions, and, consequently, may alter the biochemical and/or structural properties of the protein. In particular, in vitro and in vivo studies have shown that mutations in the c-MYC transactivation domain can deregulate c-MYC function by interfering with its phosphorylation, protein stability or the repression of its transactivation activity by the Rb-related protein p107. 8 In two PMLBCL samples, three missense mutations were found within the sequences of c-MYC exon 2 that encode the transactivation domain (Table 1) . Additionally, one missense mutation of PIM-1 affected the protein ATP-binding site, and predicted a change in the structure and, potentially, in the function of this serine/ threonine protein kinase (Table 1) .
In our study, we demonstrate that aberrant SHM affects both PMLBCL and DLBCL with similar prevalence. Moreover, the molecular profile of aberrant SHM in PMLBCL is superimposable to that observed in DLBCL and is reminiscent of the mutational spectrum of immunoglobulin variable genes. 3 In fact, mutations in the PAX-5, RhoH/TTF, PIM-1 and c-MYC proto-oncogenes (i) are predominantly represented by single nucleotide substitutions, with occasional deletions and insertions; (ii) display a preference for transitions over transversions and an elevated ratio of G þ C over A þ T substitutions; and (iii) display a preferential distribution within the RGYW/WRCY motifs. Recent reports have suggested that the mutation profile of the physiological SHM process targeting the BCL-6 gene may differ between PMLBCL and DLBCL. 5 With respect to aberrant SHM, though, our data do 
